IRCCS Humanitas Research Hospital & Humanitas University
Published January 19, 2024 | Version v1
Dataset Restricted

Dataset related to article "Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis) "

Authors/Creators

  • 1. ROR icon IRCCS Humanitas Research Hospital
  • 2. Azienda Ospedaliera San Donato Milanese
  • 3. ROR icon Azienda Ospedaliera di Cosenza
  • 4. ROR icon University of Campania "Luigi Vanvitelli"
  • 5. IRCCS Azienda Ospedaliero-Universitaria di Bologna
  • 6. ROR icon University of Genoa
  • 7. IRCCS Ospedale Policlinico San Martino
  • 8. ROR icon Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
  • 9. ROR icon University of Milan
  • 10. ROR icon University of Turin
  • 11. ROR icon Ospedale Santa Chiara
  • 12. ROR icon University of Naples Federico II
  • 13. ROR icon University of Verona
  • 14. ROR icon University of Messina
  • 15. ROR icon Azienda Ospedaliera Universitaria Policlinico "G. Martino"
  • 16. University of Modena
  • 17. ROR icon University of Bari Aldo Moro
  • 18. ROR icon Istituto Dermopatico dell'Immacolata
  • 19. ROR icon Ospedale A. Perrino
  • 20. ROR icon Humanitas University

Description

Abstract

Introduction: Brodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family. It has been approved for the treatment of moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab in a real-life setting are still limited.

Methods: The aim of this study was to evaluate the long-term effectiveness and safety of brodalumab in psoriasis. We also assessed the drug survival of brodalumab in a 3 years timespan. We conducted a retrospective multicenter study on 606 patients followed up at 14 Italian dermatology units, all treated with brodalumab according to Italian guidelines. Patients' demographics and disease characteristics were retrieved from electronic databases. At baseline and weeks 12, 24, 52, 104 and 156, we evaluated the psoriasis area and severity index (PASI) score and investigated for adverse events. The proportions of patients reaching 75, 90 and 100% (PASI 75, PASI 90 and PASI 100, respectively) improvement in PASI, compared with baseline, were also recorded.

Results: At week 12, 63.53% of the patients reached PASI 90 and 49.17% PASI 100. After 3 years of treatment, 65.22% of patients maintained a complete skin clearance, and 91.30% had an absolute PASI of 2 or less. Patients naïve to biological therapies had better clinical responses at weeks 12, 24 and 52. However, after 2 years of treatment, no significant differences were observed. Body mass index did not interfere with the effectiveness of brodalumab throughout the study. No new safety findings were recorded. After 36 months, 85.64% of our patients were still on treatment with brodalumab.

Conclusion:  Our data confirm the effectiveness and the safety of brodalumab in the largest real-life cohort to date, up to 156 weeks.

Files

Restricted

The record is publicly accessible, but files are restricted. <a href="https://zenodo.org/account/settings/login?next=https://zenodo.org/records/10531789">Log in</a> to check if you have access.

Request access

If you would like to request access to these files, please fill out the form below.

You need to satisfy these conditions in order for this request to be accepted:


This set of raw data is accessible under request because they include sensitive data.

Please provide details about your request

You are currently not logged in. Do you have an account? Log in here

Additional details

Related works

Is supplemented by
Publication: 10.3389/fmed.2023.1196966 (DOI)
Publication: 37469659 (PMID)